Skip to Main Content

Author Details

Jan Budczies
Institute of Pathology, University Hospital Heidelberg
1996
173
52
PMIDPaper TitleJournal TitlePublished Year
37558578Erratum to "Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project": [Annals of Oncology 32 (2021) 1626-1636].Ann Oncol2024
36735063Structure and content of the EU-IVDR : Current status and implications for pathology.Pathologie (Heidelb)2023
37864096Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients.NPJ Precis Oncol2023
37657453[Molecular tumor diagnostics as the driving force behind precision oncology].Dtsch Med Wochenschr2023
37792098[Regulation (EU) 2017/746 (IVDR): practical implementation of annex I in pathology].Pathologie (Heidelb)2023
37586177Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.Lung Cancer2023
38047950Regulation (EU) 2017/746 (IVDR): practical implementation of annex I in pathology.Pathologie (Heidelb)2023
37059713Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis.Cell Death Discov2023
37014668Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial.Clin Cancer Res2023
37280276The German Network for Personalized Medicine to enhance patient care and translational research.Nat Med2023
37141769Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.Lung Cancer2023
37327584Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD).Transl Oncol2023
36852573Real-world data for precision cancer medicine-A European perspective.Genes Chromosomes Cancer2023
34331337Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.Genes Chromosomes Cancer2022
35384413Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.J Pathol Clin Res2022
35642679Correction to "Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancerâ¿¿Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling".J Proteome Res2022
35598358The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.Eur J Cancer2022
35563834<i>LINC00152</i> Drives a Competing Endogenous RNA Network in Human Hepatocellular Carcinoma.Cells2022
35681079Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).NPJ Precis Oncol2022
35871236Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.Br J Cancer2022
35925306[Structure and content of the EU-IVDR : Current status and implications for pathology].Pathologie (Heidelb)2022
33631297Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling.Semin Cancer Biol2022
34863788The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients.Gastroenterology2022
34325986Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.Urol Oncol2022
34125345Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.Cancer Immunol Immunother2022
33418062Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy<sup>â¿¿</sup>.Ann Oncol2021
33686791KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas.Genes Chromosomes Cancer2021
33520406A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma.Oncoimmunology2021
33667718Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.Lung Cancer2021
34606929Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.Ann Oncol2021
34487971The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.ESMO Open2021
34012783Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma.Transl Lung Cancer Res2021
34311075The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.Ann Oncol2021
33429878Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC.Cancers (Basel)2021
31430556Decoding and targeting the molecular basis of MACC1-driven metastatic spread: Lessons from big data mining and clinical-experimental approaches.Semin Cancer Biol2020
31970771Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.Int J Cancer2020
31937923Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma.Br J Cancer2020
31784776[On the quality of the external post-mortem examination in cases of fatal head trauma : A comparison of death certificate and forensic autopsy].Anaesthesist2020
31932495A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial.Clin Cancer Res2020
31855806PARP-1 expression as a prognostic factor in Desmoid-type fibromatosis.Ann Diagn Pathol2020
31735980Updating the risk profile of fatal head trauma: an autopsy study with focus on age- and sex-dependent differences.Int J Legal Med2020
33139244Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.Cancer Discov2020
32119917Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.J Thorac Oncol2020
32212351Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing.Genes Chromosomes Cancer2020
32143116Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement.Lung Cancer2020
32234756<i>TP53</i> Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.Clin Cancer Res2020
32347317What turns CREB on? And off? And why does it matter?Cell Mol Life Sci2020
30446996Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.Int J Cancer2019
31690830Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinoma.Br J Cancer2019
31803175A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer.Front Immunol2019
  • 1 - 50 of 173

Recommended Authors

Yari Ciani
University of Trento
Career Start Year 2012
Number of shared co-authors 1
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 0
Hans Kristian Moen Vollan
F Hoffmann-La Roche Ltd
Career Start Year 2010
Number of shared co-authors 5
Charlotte K Y Ng
University of Bern
Career Start Year 2009
Number of shared co-authors 7
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 0
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 0
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 1
Karolina Edlund
Leibniz Research Centre for Working Environment and Human Factors at TU Dortmund
Career Start Year 2008
Number of shared co-authors 1
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 1
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 3
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 7
Joshy George
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 4
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 3
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 9
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 7
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 6
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 2
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 5
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 5
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 0
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 8
Loris De Cecco
Fondazione IRCCS Istituto Nazionale dei Tumori
Career Start Year 2000
Number of shared co-authors 1
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Ole Christian Lingj??rde
University of Oslo
Career Start Year 1997
Number of shared co-authors 4
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 12
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 5
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 0
Laura J Van't Veer
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 6

Collaborators

Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 70
Peter Schirmacher
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 52
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Co-authored papers 33
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 33
Martina Kirchner
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 28
Michael Allg??uer
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 26
Daniel Kazdal
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 25
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers 24
Anna-Lena Volckmar
Institut fur Pathologie, Universitatsklinikum Heidelberg
Co-authored papers 22
Olaf Neumann
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 20
Oliver Fiehn
University of California davis
Co-authored papers 12
Michael Bockmayr
Institute of Pathology, Charite Universitatsmedizin Berlin
Co-authored papers 12
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 7
Hans-Peter Sinn
Pathologisches Institut, Universitatsklinikum Heidelberg
Co-authored papers 7
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 6
Matej Ore??i??
University of Turku and Abo Akademi University
Co-authored papers 6
Julian L Griffin
Cambridge University
Co-authored papers 6
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Co-authored papers 6
Huriye Seker-Cin
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 5
Thomas Longerich
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 5
Markus Ball
Institute of Pathology, Heidelberg University Hospital
Co-authored papers 5
Benedikt Brors
German Cancer Research Center (DKFZ)
Co-authored papers 5
Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Co-authored papers 5
Philipp Jurmeister
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Co-authored papers 4
Ivo Buchhalter
German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)
Co-authored papers 4
Kristiina Iljin
VTT Technical Research Centre of Finland Ltd
Co-authored papers 4
Holger S??ltmann
German Cancer Research Center (DKFZ)
Co-authored papers 4
Elmar Bucher
Co-authored papers 4
Esther Herpel
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 4
Susanne Beck
Vrije Universiteit Brussel (VUB)
Co-authored papers 4
Release 1.2